uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The actual problems facing Swedish biotech
Uppsala University, Humanistisk-samhällsvetenskapliga vetenskapsområdet, Faculty of Social Sciences, Department of Business Studies.
Uppsala University, Humanistisk-samhällsvetenskapliga vetenskapsområdet, Faculty of Social Sciences, Department of Business Studies.
2007 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Even though Swedish Biotech has the potential to grow, the road that drug

development related projects have to travel on their way from discovery to

commercialisation is long, expensive and complicated.

One crucial step that most projects need to pass on their way to the market is the

transfer from a research intensive biotech company to a resource rich

pharmaceutical company that can pay for the last expensive development of the

product and bring it to the market. The transfer of the project often take place

through a license agreement that the biotech and the pharmaceutical company

together form during negotiations.

The structural change that the pharmaceutical industry is going through has led to

an increase of biotechnology licensing and this trend is likely to continue for yet

some years to come. The income the biotech company receives from out-licensing

their projects is often the only income they have and it is therefore crucial for the

biotech companies survival that the license agreement are formed without severe


The history of Swedish Biotechnology licensing contains several examples of

license agreement that have not brought optimal value to the biotech companies.

Because of the sudden increase of license agreements the need to study the

problems that lie in the way when Swedish biotech and pharmaceutical companies

meet to negotiate is urgent. This report therefore aims to identify some of the

actual problems that occur by analysing interviews with key persons in the field.

Both actors involved in license agreement negotiations as well as general industry

experts have been interviewed to obtain different perspectives of biotechnology

licensing. Four different issues that cover the negotiation process, the outcome of

the negotiations as well as the negotiation ability of the involved actors were

identified as the features that the respondents were most concerned about. The

identified issues have been named; parking, long negotiations, lack of experience

and the Swedish problem.

Place, publisher, year, edition, pages
Uppsala: Företagsekonomiska institutionen , 2007. , 42 p.
Keyword [en]
licence, negotiations, parking, long negotiations, lack of experience, licence agreements, biotech, sweden
National Category
Business Administration
URN: urn:nbn:se:uu:diva-8973OAI: oai:DiVA.org:uu-8973DiVA: diva2:132022
2007-05-30, Uppsala, 10:00
Available from: 2008-05-07 Created: 2008-05-07

Open Access in DiVA

No full text

By organisation
Department of Business Studies
Business Administration

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 203 hits
ReferencesLink to record
Permanent link

Direct link